A Phase II, Multicentre, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA).
Participants are randomised to 1 or 2 monthly treatment or no treatment.
Trial Registry Number: NCT02503332
